Global Gaucher
Disease Market is classified on the basis of product type, type of
treatment molecules, route of administration, dosage forms, end users, and
geography. A rare inherited disorder that results from the deficiency of the
enzyme glucocerebrosidase is known as Gaucher disease. The typical character of
this disease is that there is deposition of fatty substances in body’s organs
and tissues.
Get Details of Gaucher
Disease Market Report at : https://www.millioninsights.com/industry-reports/gaucher-disease-market
The signs and symptoms of Gaucher
disease may differ widely among people. Some of the signs and symptoms of
Gaucher disease include fatigue, enlarged liver and spleen, low platelet and
haemoglobin counts,bone pain and fractures, etc. The diagnosis of Gaucher
disease can be carried out by laboratory testing either by quantifying the
level of the enzyme glucocerebrosidase or by DNA study of the GBA gene for the
four most common GBA mutations.
There are mainly three types of
Gaucher disease. The mildest and most common type of Gaucher disease is Type 1.
The type 1 disorder is also known as Nonneuronopathic Gaucher disease and it
does not affect the nervous system.
Whereas, neuronopathic forms of
Gaucher disease are Type 2 also called as acute infantile neuronopathic Gaucher
disease and Type 3 also called as chronic neuronopathic Gaucher disease. These
types of disorder affect the central nervous system and cause severe problems
brain damage, seizures, respiratory problems, poor development, eye movement disorders,
enlarged spleen & liver, bone problems, etc.
Gaucher Disease is also known as
glucosylceramide lipidosis, cerebrosidelipidosis syndrome, kerasinlipoidosis,
glucocerebrosidase deficiency, kerasinhistiocytosis, glucosylceramide
beta-glucosidase deficiency, Gaucher splenomegaly, cglucosylceramidase
deficiency, Gaucher syndrome, glucocerebrosidosis, lipoid histiocytosis
(kerasin type), Gaucher's disease, GD, glucosylcerebrosidelipidosis and
kerasinthesaurismosis.
The factors that propel the
growth of the Gaucher Disease Market include increasing research &
development activities and specialfacility for orphan drugs. On the other hand,
there are also factors that may hamper the growth of the market such
asinadequate patient population as it is a rare disease. Gaucher Disease Market
is classified on the basis of product type asenzyme replacement therapy and
substrate reduction therapy.
Gaucher Disease Market is
classified on the basis oftype of treatment molecules as biologics, small
molecules and others. Gaucher Disease Market is classified on the basis of
route of administration asoral, and parenteral. Gaucher Disease Market is
classified on the basis of dosage forms as solid, liquid and others.
Get Sample Copy of Gaucher
Disease Market at: https://www.millioninsights.com/industry-reports/gaucher-disease-market/request-sample
Gaucher Disease Market is
classified on the basis of end users as Non-neuronopathic Gaucher disease and
Neuronopathic Gaucher disease. Gaucher Disease Market is classified on the
basis of as North America, Latin America, Western Europe, Eastern Europe, Asia
Pacific, Japan and Middle East and Africa.
The North American region
consists of the U.S., and Canada. Latin America region consists of Mexico and
Brazil. The Western European region consists of Germany, Italy, France, England
and Spain. The Eastern European region consists of Poland and Russia. Asia
Pacific region consists of China, India, ASEAN, Australia & New Zealand.
The Middle East and Africa region consists of GCC, South Africa and North
Africa. Some of the key players that fuel the growth of the market include
Actelion Pharma, Pfizer, Sanofi, Shire, and others.
No comments:
Post a Comment